金吾财讯 | 诺瓦瓦克斯医药(NVAX)涨超21%，截至发稿，报8.14美元。消息面上，美国食品药物管理局(FDA)批准诺瓦瓦克斯医药新冠病毒疫苗上市，但仅适用于老年人或12岁以上人士。
根据FDA发布的公告，此次获批的诺瓦瓦克斯医药疫苗适用于两类人群：一是65岁及以上老年群体；二是12至64岁且至少患有一种基础疾病、可能引发新冠肺炎重症的高风险人群。该批准基于关键性三期临床试验数据，根据诺瓦瓦克斯医药与赛诺菲(SNY)于2024年达成的授权协议，此次获批将触发1.75亿美元的里程碑付款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.